Literature DB >> 26605757

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Benedetta Donati1, Benedetta Maria Motta1,2, Piero Pingitore2, Marica Meroni1, Alessandro Pietrelli1,3, Anna Alisi4, Salvatore Petta5, Chao Xing6, Paola Dongiovanni1, Benedetta del Menico1, Raffaela Rametta1, Rosellina Margherita Mancina2, Sara Badiali1, Anna Ludovica Fracanzani1, Antonio Craxì5, Silvia Fargion1, Valerio Nobili4, Stefano Romeo2,7,8, Luca Valenti1.   

Abstract

UNLABELLED: The patatin-like phosholipase domain-containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early-onset NAFLD vs. very low aminotransferases) and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron-exon boundaries either in 142 patients with early-onset NAFLD nor in 100 healthy individuals with alanine aminotransferase <22/20 IU/mL. Besides rs738409 I148M, the rs2294918 G>A polymorphism (E434K sequence variant) was over-represented in NAFLD (adjusted P = 0.01). In 1,447 subjects with and without NAFLD, the 148M-434E (P < 0.0001), but not the 148M-434K, haplotype (P > 0.9), was associated with histological NAFLD and steatohepatitis. Both the I148M (P = 0.0002) and E434K variants (P = 0.044) were associated with serum ALT levels, by interacting with each other, in that the 434K hampered the association with liver damage of the 148M allele (P = 0.006). The E434K variant did not affect PNPLA3 enzymatic activity, but carriers of the rs2294918 A allele (434K) displayed lower hepatic PNPLA3 messenger RNA and protein levels (P < 0.05).
CONCLUSIONS: Rare loss-of-function PNPLA3 variants were not detected in early-onset NAFLD. However, PNPLA3 rs2294918 E434K decreased PNPLA3 expression, lessening the effect of the I148M variant on the predisposition to steatosis and liver damage. This suggests that the PNPLA3 I148M variant has a codominant negative effect on triglycerides mobilization from lipid droplets, mediated by inhibition of other lipases.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26605757     DOI: 10.1002/hep.28370

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.

Authors:  Noura S Abul-Husn; Xiping Cheng; Alexander H Li; Yurong Xin; Claudia Schurmann; Panayiotis Stevis; Yashu Liu; Julia Kozlitina; Stefan Stender; G Craig Wood; Ann N Stepanchick; Matthew D Still; Shane McCarthy; Colm O'Dushlaine; Jonathan S Packer; Suganthi Balasubramanian; Nehal Gosalia; David Esopi; Sun Y Kim; Semanti Mukherjee; Alexander E Lopez; Erin D Fuller; John Penn; Xin Chu; Jonathan Z Luo; Uyenlinh L Mirshahi; David J Carey; Christopher D Still; Michael D Feldman; Aeron Small; Scott M Damrauer; Daniel J Rader; Brian Zambrowicz; William Olson; Andrew J Murphy; Ingrid B Borecki; Alan R Shuldiner; Jeffrey G Reid; John D Overton; George D Yancopoulos; Helen H Hobbs; Jonathan C Cohen; Omri Gottesman; Tanya M Teslovich; Aris Baras; Tooraj Mirshahi; Jesper Gromada; Frederick E Dewey
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

2.  Missense Mutant Patatin-Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGI-58.

Authors:  Scott McHenry; Nicholas O Davidson
Journal:  Hepatology       Date:  2019-04-25       Impact factor: 17.425

Review 3.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

Review 4.  Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology.

Authors:  Silvia Sookoian; Carlos J Pirola; Luca Valenti; Nicholas O Davidson
Journal:  Hepatology       Date:  2020-07       Impact factor: 17.425

Review 5.  NAFLD in children: new genes, new diagnostic modalities and new drugs.

Authors:  Valerio Nobili; Anna Alisi; Luca Valenti; Luca Miele; Ariel E Feldstein; Naim Alkhouri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07-05       Impact factor: 46.802

6.  Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population.

Authors:  Xiaoliang Wang; Zhipeng Liu; Kai Wang; Zhaowen Wang; Xing Sun; Lin Zhong; Guilong Deng; Guohe Song; Baining Sun; Zhihai Peng; Wanqing Liu
Journal:  Front Genet       Date:  2016-08-02       Impact factor: 4.599

7.  Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.

Authors:  Wanqing Liu; Quentin M Anstee; Xiaoliang Wang; Samer Gawrieh; Eric R Gamazon; Shaminie Athinarayanan; Yang-Lin Liu; Rebecca Darlay; Heather J Cordell; Ann K Daly; Chris P Day; Naga Chalasani
Journal:  Aging (Albany NY)       Date:  2016-10-13       Impact factor: 5.682

Review 8.  Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.

Authors:  Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

9.  PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.

Authors:  Gemma Aragonès; Teresa Auguet; Sandra Armengol; Alba Berlanga; Esther Guiu-Jurado; Carmen Aguilar; Salomé Martínez; Fátima Sabench; José Antonio Porras; Maikel Daniel Ruiz; Mercé Hernández; Joan Josep Sirvent; Daniel Del Castillo; Cristóbal Richart
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

Review 10.  Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.